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Overdiagnosis and overtreatment over time
Abstract: Overdiagnosis and overtreatment are often 
thought of as relatively recent phenomena, influenced 
by a contemporary combination of technology, speciali-
zation, payment models, marketing, and supply-related 
demand. Yet a quick glance at the historical record reveals 
that physicians and medical manufacturers have been 
accused of iatrogenic excess for centuries, if not millen-
nia. Medicine has long had therapeutic solutions that 
search for ever-increasing diagnostic problems. Whether 
the intervention at hand has been leeches and lancets, 
calomel and cathartics, aspirins and amphetamines, or 
statins and SSRIs, medical history is replete with skeptical 
critiques of diagnostic and therapeutic enthusiasm. The 
opportunity cost of this profusion shapes the other side 
of the coin: chronic persistence of underdiagnosis and 
undertreatment. Drawing from key controversies of the 
19th and 20th centuries, we chart the enduring challenges 
of inter-related diagnostic and therapeutic excess. As the 
present critique of overdiagnosis and overtreatment seeks 
to mobilize resources from inside and outside of medicine 
to rein in these impulses, we provide an instructive his-
torical context from which to act.
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Introduction
In recent years, an increasing number of clinicians, jour-
nalists, health service researchers, and policy-makers 
have drawn attention to the problems of overdiagnosis 
and the overtreatment that it so often engenders [1, 2]. 
Proliferating screening modalities, diagnostic tests, and 
imaging platforms, often accompanied by strong market-
ing and weak oversight, present otherwise healthy people 
with diagnoses that may well lead to more harm than 
good. Using a variety of descriptions – disease-mongering 
[3], diagnostic creep [4], or medicalization [5] – critics 
have pointed to the need to address the issue of overdi-
agnosis before we enact irreparable cost and harm to our 
bodies, pocketbooks, and health care systems.
Even though this problem has become particularly 
acute in the early 21st century, the critique of overdiagno-
sis is as old as biomedicine itself. Under different terms, 
overdiagnosis has been iteratively rediscovered since 
the introduction of laboratory sciences and extensive 
diagnostic technologies into the field of medicine in the 
late 19th century. This paper, a brief historical survey of 
concerns about overdiagnosis, suggests these concerns 
are grounded in several areas: broader anxieties about 
the rapidly changing practice of medicine, especially as 
regards the link between medicine and technology; the 
interface between medicine and the marketplace; and 
the prioritization of limited resources within the arena of 
health intervention.
Medicine and the reign 
of technology
Many critiques of overdiagnosis are tales of technology 
run amok. As powerful as our diagnostic technologies 
have become, the use of imaging techniques and screening 
modalities now leads to countless invasive interventions 
on people who may well have lived otherwise perfectly 
healthy lives [6]. How does one interpret a 3  mm lung 
nodule? An “elevated” PSA test? What kinds of findings 
necessitate action, and how do we know such action helps?
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The seeds of these dilemmas can be already seen in 
the first decade of the 20th century, as the concept of a 
specific diagnostic blood test was first being developed in 
the research laboratory of the syphilologist August Was-
sermann. After its introduction in 1906, the Wassermann 
test for syphilis was applied in many domains outside 
the syphilis clinic, from military screening to marriage 
licenses. Clinicians and laboratory researchers at the time 
knew that the test needed to be calibrated and interpreted 
(Figure 1) [7]; as the Polish microbiologist and sociologist 
Figure 1: Reading of results of the Wasserman test.
Craig, Charles Franklin. The Wassermann test. Published with 
authority of the Surgeon General, United States Army. St. Louis: 
Mosby, 1918, p. 98.
Figure 2: The sad irony is that false positive rates themselves lead 
to “false shame and fear.”
Krause EH. Syphilis False shame and fear may destroy your future: 
Have your blood tested.1938. Available at: http://www.loc.gov/
pictures/item/98514501/.
Lukwik Fleck later described, the final steps in producing 
the Wassermann test were like “tuning a [radio] set” [8]. 
The stakes were high: the medical literature soon became 
filled with accounts of “false positive” Wassermann 
results that led to toxicity from unnecessary treatment 
with arsenicals and mercurials, the rejection of healthy 
men from military service, and the calamitous prohibition 
of marriage and accumulation of social stigma among 
individuals who were free from disease (Figure 2) [9, 10].
The deeper fear that physicians may lose agency to 
diagnostic technology preceded even the Wassermann 
test. Oliver Wendell Holmes, in his 1848 Stethoscope Song, 
described to comic effect the misdiagnosis of empyema 
based on the presence within a hapless physician’s steth-
oscope of unwanted flies, who buzz upon being pressed 
against a sick man’s chest:
Then out his stethoscope he took, 
And on it placed his curious ear; 
Mon Dieu! said he, with a knowing look, 
Why, here is a sound that’s mighty queer!
The bourdonnement is very clear, – 
Amphoric buzzing, as I’m alive! 
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Five doctors took their turn to hear; 
Amphoric buzzing, said all the five.
There’s empyema beyond a doubt 
We’ll plunge a trocar in his side. 
The diagnosis was made out, – 
They tapped the patient; so he died [11].
This was literal “noise,” but since Holmes’ time, critiques 
of diagnostic technology have been closely bound up in 
fears of more metaphorical noise (as opposed to signal) 
and of the runaway power of technology in medicine. 
From the vantage point of the present, some of these past 
fears may appear overstated (in the 21st century, the steth-
oscope is no longer seen as a barrier between doctor and 
patient), others understated (clinicians all understand the 
problem of the false positive yet we act as if our test results 
are absolute).
Either way, false positives of all sorts can lead to both 
misdiagnosis and overdiagnosis, with potential down-
stream consequences. And the image of the diagnostic 
technological Sorcerer’s Apprentice – inherently difficult 
to control – has persisted. In 1937, cardiologist Paul Dudley 
White wished aloud for a more specific test to limit the 
“overdiagnosis” of coronary thrombosis then taking place 
in hospitals around the country, lamenting: “I now spend 
more time in excluding the diagnosis of coronary thrombo-
sis than in correcting some other diagnosis.” [12]. Decades 
after his death, White’s dreams would seemingly be real-
ized in the widespread application of cardiac troponin 
testing as a specific blood test for myocardial infarction. 
Yet as with the Wassermann, the troponin test contains its 
fair share of false positives and “gray area” interpretative 
challenges [13]. In other words, even technologies devel-
oped to limit overdiagnosis can paradoxically reproduce 
the problem they were intended to resolve.
Medicine and the marketplace
Critics of overdiagnosis have also extended their suspi-
cions beyond the uncaring, disinterested realm of medical 
technology to actors who are far too interested: those who 
profit directly from the increased diagnosis (and typically 
treatment) of populations of patients who would have 
likewise fared just as well, if not better, had they been 
left undiagnosed and untreated. Over the past decade, 
Ray Moynihan and Alan Cassels’ influential Selling Sick-
ness [14] has been joined by other voices in a movement to 
identify and expose examples of ‘disease-mongering.’ In 
a few egregious cases, such as the direct manipulation of 
the category of ‘social anxiety disorder’ into a marketable 
condition to expand sales of Paxil, the benefits to pharma-
ceutical corporations in selling sickness appear to grossly 
outweigh the likely public health or clinical benefits to 
those diagnosed [15]. In many other cases, however, the 
collision of financial interests and public health benefit is 
much harder to untangle.
Concerns regarding the effects of Mammon on the 
purity of diagnostic categories are not unique to the 21st 
century. Consider, for example, the status of diabetes 
before and after the marketing of the first oral antidiabetic 
agent, Upjohn’s Orinase (tolbutamide), in 1957. The devel-
opment of insulin in the 1920s had changed diabetes from 
a death sentence into a chronic condition. But the prac-
tice of insulin administration entailed a heavy burden and 
was only accepted by patients who had frankly clinical 
diabetes, that is, at least evidence of sugar in the urine if 
not frank symptoms of polydipsia, polyuria, and autopha-
gia on diagnosis.
The development of Orinase created new horizons 
for Upjohn’s marketers and diabetologists alike, in the 
emerging field of “prediabetes” or “chemical diabetes.” 
[16]. Why wait for evidence of sugar in the urine when a 
far larger population of people could be diagnosed and 
treated on the basis of high fasting blood sugar alone? 
In the early 1950s, such individuals would not have been 
considered diabetics. By the middle of the 1960s, mil-
lions of people with this “chemical diabetes” had been 
diagnosed and placed on regimens of Orinase indefi-
nitely. Upjohn funded several academic diabetologists to 
research the logic of early treatment. From the perspective 
of public health officials, this was a progressive venture to 
intervene on the dread disease of diabetes long before loss 
of life or limb. From the perspective of Upjohn’s market-
ers, expanded screening, diagnosis, and treatment helped 
Orinase sales expand to ever-larger populations of newly 
defined patients.
Several critics within academic medicine and con-
sumer advocacy groups, however, asked whether the 
widespread treatment of “asymptomatic diabetes” was 
justified on any grounds beyond theory and marketing, 
or whether it constituted a widespread and uncontrolled 
experiment in medical intervention on large populations. 
Mass screening for chemical diabetes, from this perspec-
tive, became a key example of overdiagnosis and over-
treatment, led by the improper collusion of a small group 
of diabetes specialists and a powerful market incentive. As 
the controversy rankled and deepened, the NIH agreed to 
fund a multi-arm study of unprecedented scale, the Uni-
versity Group Diabetes Project (UGDP), to settle whether 
intervention with tolbutamide could be found to produce 
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any benefit in patients with asymptomatic diabetes. 
All parties were surprised, however, when the trial was 
aborted early not due to lack of evidence but due to evi-
dence of harm: the tolbutamide arm showed increased 
cardiovascular mortality compared to placebo [17].
In the years since the UGDP study, the initial consen-
sus on the prevention of neuropathy, nephropathy, and 
retinopathy via glucose reductions has been questioned 
[18]. Debate over the proper public health calibration of 
the ideal HbA1c also persists, as does the cost-benefit of 
enrolling populations with borderline glucose metabolism 
into regimens of long-term pharmacotherapy [19]. The 
story of Orinase illustrates the hidden risks to “win-win” 
collusions between public health and private markets.
Overdiagnosis and underdiagnosis
Finally, throughout history critiques of overdiagnosis 
have been fueled by a third concern: that attention given 
to diagnosing and treating conditions of negligible clini-
cal or public health value comes at the cost of neglecting 
conditions of real significance.
These opportunity costs are perhaps most tragically 
evident in the case of mental health. Since the labeling 
and antipsychiatry critiques of the 1960s and 1970s – and 
through the subsequent debates in the 1980s and 1990s 
over the expanding role of anxiolytics, antidepressants, 
and psychostimulants in everyday life – the field of psychi-
atry has long been the subject of critiques of overdiagnosis 
[20]. And yet at the same time that the “worried well” of the 
middle class are supposedly consuming record amounts of 
psychopharmaceuticals in conjunction with an expansive 
lexicon of mental disorders (15 new diagnoses were added 
between DSM-IV and DSM V), a core subset of individuals 
who are unquestionably suffering from major psychotic or 
affective disorders remain untreated or undertreated [21]. 
Over the past half-century, the US has exchanged a flawed 
system of institutionalized care for a system of non-care 
and subsequent mass incarceration; the percentage of 
inmates with serious mental illness now approaches that 
of the 1840s [22]. Recent data suggest that fewer than half 
of those in the general population with a mental health 
disorder received treatment, while only 10% of those with 
substance addictions other than nicotine are able to find 
treatment in the health care system [23].
This critique only builds in valence when one links 
the markets for overtreatment in the global North with the 
structures of market failure that lead to undertreatment in 
the global South – not only in terms of mental health, but 
also in terms of cancer care, cardiovascular health, and 
other noncommunicable diseases [24]. This, too, can be 
traced back almost a half century: One of the World Health 
Organization’s first symposia on the Consumption of 
Drugs, held in Oslo in 1969, explicitly compared the over-
consumption of pharmaceuticals in rich European coun-
tries with their relative underconsumption in other parts 
of the world [25]. In 1971, Julian Tudor Hart codified this 
effect as the Inverse Care Law: “The availability of good 
medical care tends to vary inversely with the need for it in 
the population served” [26, 27]. Part of the longstanding 
moral critique against overdiagnosis and overtreatment of 
trivial conditions, then, is that it is linked to underdiagno-
sis and undertreatment of substantial ones.
Conclusions
As this brief review has demonstrated, while the critique 
of overdiagnosis has become uniquely resonant in the 
early 21st century, it is not at all new. Concerns about over-
diagnosis – by one name or another – have been present 
in some form since before the 20th century. These con-
cerns are not sporadic or random but are clearly related 
to broader concerns about the intersection of medical 
science, medical industry, medical policy, and medical 
practice. Tracing the fate of overdiagnosis over time alerts 
us to larger relationships between medicine and techno-
logy, medicine and industry, and medicine and the focus 
of its analysis and interventions. As medicine continues 
to evolve in the 21st century, we suspect that such endur-
ing concerns will persist. The history of overdiagnosis 
teaches us that the problem we are facing is not something 
extrinsic to medicine, or something that has been recently 
acquired, but a demon at the heart of the biomedical 
enterprise that we must continue to work to tame so that 
our collective efforts might help more than harm those 
whom we serve.
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